News – Page 1091 – Endpoints News

SIGN UP

Viking leads a $46M raise for a struggling aTyr Pharma

8 years ago

Aveo takes a big step forward as comeback plan delivers EU OK for tivo

8 years ago

CSL snags a preclinical stem cell therapy in $416M Calimmune buyout, plans to spin out HIV effort

8 years ago

Diving deep into CAR-T, Gilead forges $12B buyout deal for Kite Pharma

8 years ago

Novartis team scores a pioneering first in cardio R&D. But can they sell it?

8 years ago

Novartis recruits a global digital chief; Shire CFO jumps ship

8 years ago

Novartis’ Kisqali to go head-to-head with Pfizer’s Ibrance; USC joins regional biotech alliance

8 years ago

After a long, painful revamp, Merck KGaA scores key OK for once-defunct MS drug cladribine

8 years ago

Novartis returns to the discount aisle, buys Xoma's failed PhIII drug for $31M

8 years ago

Regenxbio bags one of its gene therapy vector partners, buying out a struggling Dimension

8 years ago

Pfizer has found a stylish new home for its HQ in Manhattan — report

8 years ago

After a long clinical odyssey, the FDA tapped this PhIII anti-CCR4 as a ‘breakthrough’ lymphoma drug

8 years ago

Adamas wins its first FDA OK, setting up market launch for a reformulated Parkinson’s drug

8 years ago

Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger

8 years ago

On a roll, Apellis adds positive PhII C3 data for AMD drug, preps for PhIII

8 years ago

Troubled ImmunoCellular slashes costs, jobs in restructuring; Accelerated Pharma dumps struggling IPO effort

8 years ago

Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab

8 years ago

Meet Bertrand Bodson, Novartis’ new global digital strategy maestro for all things Big Pharma

8 years ago

AstraZeneca researchers plumb positive data to back extended use of Brilinta

8 years ago

EMA and FDA will now share trade secrets, allowing both regulators to act on each other's inspection reports

8 years ago

Key figure in notorious biopharma insider case loses an appeal — broadening scope for future cases

8 years ago

Can Amgen beat down payer resistance to Repatha with its own cost analysis?

8 years ago

Here’s why 23-year-old Laura Deming is betting $22M on anti-aging R&D

8 years ago

Amgen backs a fresh raise for AI player GNS Healthcare; SQZ names Agarwal as new CMO

8 years ago

First page Previous page 1088 1089 109010911092 1093 1094 Next page Last page